WebApr 19, 2024 · “TwinRCTs not only increase trial efficiency but also provide rigorous evidence suitable for supporting regulatory decisions.” According to the company, the treatment effects for the primary and secondary outcomes can all be estimated with greater precision after correcting for each patient’s prognostic score derived from their digital twin. WebSep 28, 2024 · Unlearn.AI is the only company creating TwinRCTs, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer …
Unlearn Receives Draft Qualification Opinion from European ... - BioSpace
WebMay 12, 2024 · Unlearn.AI is the only company creating TwinRCTs™, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials. Unlearn’s technology has been published in conference abstracts and scientific journals, including Scientific Reports – Nature and The International Journal of Biostatistics. WebApr 19, 2024 · Unlearn.AI is the only company creating TwinRCTs™, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials. myrtleford dorevitch
Unlearn raises Series B funds to advance TwinRCTs usage in …
WebSep 28, 2024 · Unlearn.AI is the only company creating TwinRCTs, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. WebNov 9, 2024 · TwinRCTs control for bias and produce regulatory-acceptable evidence across all disease indications. ECAs, on the other hand, introduce bias and therefore have … WebApr 20, 2024 · Machine-learning technology developer Unlearn has raised $50m in a Series B financing round led by US-based global venture capital and private equity firm Insight Partners to advance the use of TwinRCTs in clinical trials. New investor Radical Ventures and current investors of the company, including DCVC, 8VC, Mubadala Capital Ventures … the source rightanswers.com